<DOC>
	<DOCNO>NCT00002657</DOCNO>
	<brief_summary>RATIONALE : Reducing amount drug use prevent transplant rejection may help person 's body kill tumor cell . Giving biological therapy , interferon alfa , may interfere growth cancer cell , combination chemotherapy , use different way stop tumor cell divide stop grow die , may kill tumor cell . PURPOSE : Phase II trial study effectiveness reduce immunosuppression , give interferon alfa combination chemotherapy , treat patient malignant tumor develop organ transplant .</brief_summary>
	<brief_title>SWOG-9239 Reduction Immunosuppression Plus Interferon Alfa Combination Chemotherapy Treating Patients With Malignant Tumors That Develop After Organ Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete remission rate survival patient lymphoproliferation follow organ transplantation treat defined sequential approach : modification immunosuppression , surgery limit radiotherapy isolate site disease ; interferon alfa ; chemotherapy ( ProMACE-CytaBOM ; cyclophosphamide , doxorubicin , etoposide , prednisone , cytarabine , bleomycin , vincristine , methotrexate ) . OUTLINE : All patient receive modification immunocompetence , unless rejection present outset . These patient proceed directly interferon treatment . Group 1 ( see Disease Characteristics ) : Patients receive reduce dos current immunosuppressive therapy 10 day . Group 2 : Patients receive reduce dos current immunosuppressive therapy discontinue therapy 14 day . Immunosuppressive therapy resume day 15 . Immunosuppressive therapy continue throughout therapy , unless otherwise note . Some patient may undergo surgery radiotherapy . Interferon therapy : Patients receive interferon alfa ( IFNA ) subcutaneously intramuscularly day 1-28 maximum 3 course . Patients receive maintenance therapy IFNA 3 day week 4 week 6 course . Chemotherapy ( ProMACE-CytaBOM ) : Immunosuppressive therapy stop day 1-20 . Patients receive cyclophosphamide IV , doxorubicin IV , etoposide IV 60 minute day 1 , oral prednisone day 1-14 , cytarabine IV , bleomycin IV , vincristine IV , methotrexate IV day 8 . Treatment repeat every 21 day 6 course . Patients positive CSF cytology receive intrathecal methotrexate cytarabine day 1 , 3 , 5 , 7 , 14 . Some patient may continue therapy day 21 , every 3 week 5 dos , may receive cranial irradiation . Patients follow monthly 1 year , every 2 month 1 year , every 4 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven lymphoproliferation follow organ ( kidney , liver , heart ) allograft Bidimensionally measurable disease If disease remove biopsy , eligible recurrence bidimensionally measurable Group 1 ( clinically urgent disease ) : Histologically proven involvement allograft OR Histologically proven bone marrow involvement OR Liver involvement hepatic insufficiency Bilirubin great upper limit normal ( ULN ) OR SGOT SGPT least 2 time ULN OR Clinical hepatic encephalopathy OR LDH least 3 time ULN OR Systemic sepsis OR Locally urgent lesion Tonsillar enlargement threaten airway Superior vena cava syndrome Bilateral hydronephrosis Postobstructive pneumonia OR Small noncleaved lymphocytic lymphoma ( i.e. , adult Burkitt 's lymphoma ) Group 2 : All patient No CNS disease PATIENT CHARACTERISTICS : Age : 15 Performance status : Not specify Hematopoietic : Not specify Hepatic : See Disease Characteristics Renal : Not specify Cardiovascular : See Disease Characteristics Pulmonary : See Disease Characteristics Other : No known AIDS , HIVassociated complex , positive HIV antibody No malignancy within past 5 year , except : Adequately treat basal squamous cell skin cancer Adequately treat stage I II cancer noninvasive cancer Carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon lymphoma No prior bone marrow transplantation Chemotherapy : No prior chemotherapy lymphoma Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : Intraaortic balloon pump allow heart failure cause acute rejection lymphomatous involvement</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage II small lymphocytic lymphoma</keyword>
	<keyword>stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>